Y-27632 dihydrochloride: Selective ROCK Inhibitor for Cytoskeletal and Cancer Research

Executive Summary:
Y-27632 dihydrochloride is a potent, small-molecule inhibitor with high selectivity for ROCK1 and ROCK2, exhibiting an IC₅₀ of ~140 nM and Ki of 300 nM, respectively (APExBIO product page). It inhibits Rho-mediated cellular stress fiber formation and modulates cell cycle progression from G1 to S phase with minimal off-target effects. Y-27632 improves stem cell viability and supports robust experimental outcomes in tumor invasion and metastasis models (Ni et al., 2022). Its physicochemical properties, including high solubility in DMSO (≥111.2 mg/mL), make it ideal for diverse cell-based assays. Recent peer-reviewed studies and internal benchmarks confirm its utility in advanced neurodevelopmental, cancer, and stem cell research platforms.

Biological Rationale

Rho-associated protein kinases (ROCK1 and ROCK2) are serine/threonine kinases that regulate actin cytoskeleton organization, cell contractility, and migration. Dysregulation of the Rho/ROCK signaling pathway contributes to pathologies such as cancer progression, neurodegeneration, and impaired stem cell viability (Ni et al., 2022). Selective inhibition of ROCK activity enables mechanistic dissection of cytoskeletal dynamics, cell proliferation control, and the molecular basis of tumor invasion. The ability to precisely modulate these pathways underpins the widespread adoption of Y-27632 dihydrochloride in both basic and translational research settings.

Mechanism of Action of Y-27632 dihydrochloride

Y-27632 dihydrochloride is a cell-permeable, reversible inhibitor that targets the ATP-binding catalytic domains of ROCK1 and ROCK2. Its inhibitory constants (IC₅₀: ~140 nM for ROCK1; Ki: 300 nM for ROCK2) reflect high affinity and selectivity (>200-fold) versus unrelated kinases such as PKC, PKA, MLCK, and PAK (APExBIO). Upon administration, Y-27632 blocks phosphorylation of downstream targets like myosin light chain (MLC), LIM kinase, and cofilin. This leads to disruption of actin stress fiber formation, altered cellular morphology, and inhibition of cytokinesis. Inhibition of ROCK signaling has been shown to arrest cell cycle progression at the G1/S checkpoint and reduce contractility-dependent cell migration (see our cytoskeletal troubleshooting guide, which Y-27632 dihydrochloride mechanistically extends by detailing early-phase cell cycle impacts).

Evidence & Benchmarks

• Y-27632 dihydrochloride selectively inhibits ROCK1/2 catalytic activity with minimal cross-reactivity to PKC or MLCK (APExBIO, product data).
• In vitro, Y-27632 reduces proliferation of prostatic smooth muscle cells in a dose-dependent manner (APExBIO, datasheet).
• In vivo, administration in mouse tumor models reduces pathological structures and suppresses tumor invasion/metastasis (Ni et al., 2022).
• Y-27632 enhances survival and passaging efficiency of human iPSCs and ESCs, facilitating robust pluripotency maintenance (Ni et al., 2022).
• The compound displays solubility of ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, and ≥52.9 mg/mL in water, supporting diverse experimental setups (APExBIO, product page).

Applications, Limits & Misconceptions

Research Applications

• Stem Cell Viability Enhancement: Y-27632 supports survival of dissociated iPSCs and ESCs, reducing apoptosis during cell passaging and single-cell manipulations (Ni et al., 2022).
• Cytoskeletal Studies: Enables precise modulation of actin filament assembly for cell morphology research (prior coverage of cytoskeletal modulation).
• Cancer Research: Y-27632 inhibits pathways involved in tumor cell invasion, migration, and metastasis, making it valuable for in vitro and in vivo oncology models (see neuroepigenetic and cancer invasion insights).
• Cell Proliferation Assays: Used to dissect Rho/ROCK signaling contributions to G1/S phase progression and cytokinesis (expanded in our mechanistic deep-dive).

Common Pitfalls or Misconceptions

• Y-27632 is not a pan-kinase inhibitor; it is highly selective for ROCK1/2 and does not significantly inhibit PKC, MLCK, PAK, or PKA at working concentrations (APExBIO).
• Not all cell types respond identically; some may require higher or lower concentrations for optimal results.
• The compound does not reverse established cytoskeletal defects in terminally differentiated cells; effects are most prominent during dynamic remodeling phases.
• Long-term storage of solutions (> several months) can decrease potency; always prepare fresh working stocks when possible (APExBIO).
• Not intended for therapeutic use in humans; for research applications only.

Workflow Integration & Parameters

Y-27632 dihydrochloride (SKU A3008) is provided as a solid and should be stored desiccated at 4°C or below. For solution preparation, dissolve at ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, or ≥52.9 mg/mL in water. Warming to 37°C or using an ultrasonic bath can increase solubility. Stock solutions are stable below -20°C for several months, but routine preparation of fresh aliquots is advised. In cell culture, typical working concentrations range from 10–50 μM, but optimization may be necessary depending on cell type and application. The product is compatible with high-throughput screening, stem cell maintenance, and tumor invasion assays. For advanced troubleshooting, see the scenario-driven guidance in our cell viability and proliferation workflow article, which this dossier updates for A3008 specificity and storage considerations.

Conclusion & Outlook

Y-27632 dihydrochloride, as manufactured by APExBIO, is a benchmark tool for selective ROCK inhibition in advanced cell biology, stem cell, and cancer research. Its potency, solubility, and workflow compatibility facilitate reproducible results across a wide range of experimental systems. As new disease models and drug screening platforms emerge, Y-27632 is expected to remain central to the study of Rho/ROCK signaling and its implications for cytoskeletal regulation, cell cycle control, and cell viability (for actionable workflows in neurodevelopmental and cancer models, see comparative context here).